FOXO4-DRI is an experimental senolytic peptide studied mainly in cells and mice, not a proven human longevity treatment, and it is not FDA approved for human use. It is not part of Chia’s current treatment catalog. People considering any peptide should avoid self-experimentation with research-only products and speak with a licensed clinician about evidence, risks, and appropriate options.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →What is FOXO4-DRI peptide?
FOXO4-DRI is a lab-designed peptide built to target a pathway that helps some senescent cells stay alive. It is sometimes called Proxofim, FOXO4 D-retro-inverso peptide, or a senolytic peptide, meaning a compound studied for clearing senescent cells rather than simply slowing their signals 1.
FOXO4-DRI, Proxofim, and D-retro-inverso peptide design
A peptide is a short chain of amino acids. In a D-retro-inverso design, the amino acid sequence is reversed and built from D-amino acids, which are mirror-image forms of the amino acids found in most human proteins. This design can make a peptide harder for enzymes to break down in lab and animal systems 1.
That design choice is part of why FOXO4-DRI drew attention in longevity research after a 2017 Cell paper reported senescent-cell targeting in mice 1. But a stable research peptide is not the same thing as a medication with human safety, dosing, manufacturing, and outcome data.
Why it is discussed as a senolytic longevity peptide
Senescent cells are cells that have stopped dividing but remain metabolically active. Some release inflammatory signals called the senescence-associated secretory phenotype, or SASP, which has been linked to aging biology and age-related disease pathways 6.
FOXO4-DRI is discussed as a senolytic because it was designed to disrupt a FOXO4-p53 interaction that may help senescent cells avoid apoptosis, the body’s programmed cell-death process 1. The key limit is simple: this is a promising lab mechanism, not proof that the peptide extends human lifespan or safely improves aging in people.
What are the quick facts about FOXO4-DRI?
The short answer: FOXO4-DRI is research-stage, not a clinician-standard treatment. The published evidence does not establish human dose, route, safety monitoring, side-effect rates, or longevity outcomes.
| Question | Plain answer |
|---|---|
| Evidence status | Cell and animal research. Human benefit is not established 1, 2. |
| FDA status | Not listed as an FDA-approved drug for human use. FDA approval applies to specific reviewed products, not research-use vials 5. |
| Chia availability | Not offered in Chia’s current public treatment catalog. |
| Main safety issue | Unknown human dosing, route, sterility, adverse-event rates, and long-term effects. |
| Better access model for peptides | A licensed-provider evaluation and, when appropriate, dispensing through a state-licensed 503A pharmacy for treatments that are actually offered 3. |
Can you buy FOXO4-DRI peptide for human use?
FOXO4-DRI may appear online as a research-use product, but that is not the same as a prescribed medication for a person. A vial sold for laboratory research does not come with FDA-reviewed human labeling, approved indications, established dosing, or a clinician’s safety plan 5.
Research-use products are not the same as prescribed medications
Research-use-only products are meant for laboratory work, not self-treatment. Even when a vendor page uses medical-sounding words, that does not turn the product into an FDA-approved medication or a clinician-prescribed compounded medication 5.
At Chia, the safety line we focus on is licensed versus unlicensed. For treatments we do offer, care starts with an online health questionnaire, then a licensed US provider reviews whether treatment is clinically appropriate. If prescribed, medication is compounded by a US state-licensed 503A pharmacy and shipped to the patient’s door 3.
Why identity, purity, sterility, and dose accuracy matter
For any injectable or nasal peptide, the label on a vial is only one part of safety. Identity, purity, sterility, concentration, storage, and dose accuracy all matter. Sterile compounding standards exist because contamination or concentration errors can cause harm, especially when a product is injected 8.
Why vendor claims should not be treated as clinical evidence
A product page is not a clinical trial. For FOXO4-DRI, the key published findings come from preclinical research, including a mouse study and cell models 1, 2. Claims about anti-aging, tissue repair, or lifespan in humans should not be accepted unless they are backed by human clinical data.
What does the research actually show about FOXO4-DRI?
The honest answer is that FOXO4-DRI has interesting preclinical data, but not the kind of human evidence needed to call it a treatment. The strongest claims should stay limited to cells and mice.
Cell studies: FOXO4-p53 disruption and senescent-cell apoptosis
In the 2017 Cell study, researchers reported that FOXO4 was increased in senescent cells and helped keep p53 in the nucleus. FOXO4-DRI was designed to interfere with that FOXO4-p53 interaction, which shifted p53 signaling and promoted apoptosis in senescent cells in preclinical models 1.
A later endothelial-cell senescence study also discussed FOXO4-DRI in relation to p53-linked senescence pathways 2. That supports discussion of mechanism, but it still does not show that FOXO4-DRI is safe or effective as a human longevity therapy.
Mouse studies: fitness, fur density, kidney markers, and senescence markers
In mice, Baar and colleagues reported changes in senescence markers and functional measures after FOXO4-DRI exposure, including physical activity, fur density, and kidney-related markers in specific experimental settings 1. These results are often why people search for FOXO4-DRI as a longevity peptide.
Those findings are not a dosing guide. The same paper used controlled animal models, research-grade methods, and lab monitoring that do not translate into instructions for a person. Individual human benefit, side effects, and risk level are unknown.
What the research does not show: human anti-aging, lifespan extension, or safe dosing
The available studies do not prove human lifespan extension, safe human dosing, safe self-injection, or broad anti-aging effects. Longevity science often starts in cells and animals, but many ideas that look promising there do not become safe, useful human therapies 6, 7.
How is FOXO4-DRI supposed to work?
FOXO4-DRI is meant to push certain senescent cells toward apoptosis by interrupting FOXO4-p53 signaling. That is the theory; it is not proof that the peptide is safe for people.
Senescent cells and the FOXO4-p53 survival pathway
Senescent cells can be useful in short bursts, such as during wound healing or tumor-suppression responses. Problems may arise when senescent cells build up and keep releasing SASP signals that affect nearby tissue 6.
FOXO4 is a transcription factor, a protein that helps control gene activity. p53 is a major stress-response protein involved in DNA damage, cell-cycle arrest, and apoptosis. In senescent-cell models, FOXO4-p53 binding appears to help some damaged cells survive instead of undergoing programmed cell death 1.
Why disrupting FOXO4-p53 may trigger apoptosis in senescent cells
The research idea is that FOXO4-DRI competes with normal FOXO4-p53 binding. When that interaction is disrupted, p53 can shift toward pathways that lead senescent cells to die by apoptosis 1.
Why a plausible mechanism is not the same as a proven treatment
Mechanism matters, but it is only the first step. A treatment also needs human pharmacology, safety data, adverse-event tracking, manufacturing controls, and clear clinical outcomes. FOXO4-DRI does not yet have that evidence base for human use.
What are the safety risks and unknowns?
The main safety issue with FOXO4-DRI is not one known side effect; it is the lack of human safety data. Unknowns include route, dose range, monitoring, drug interactions, immune effects, and long-term tissue effects.
No established human dose, route, or monitoring plan
The supplied FOXO4-DRI evidence does not establish a human dose, route, or lab-monitoring plan 1, 2. That matters because a peptide’s risk can change by route, concentration, frequency, patient health history, and product quality.
Potential concerns around tissue repair, cancer biology, and off-target effects
Senescent cells are not always bad. They can take part in wound healing, tissue remodeling, and cancer-suppression biology 6. A senolytic approach that removes senescent cells could have different effects depending on timing, tissue, disease state, and patient risk factors.
That is why benefits and risks must be studied together. For FOXO4-DRI, preclinical reports are not enough to define human contraindications, cancer-related risks, reproductive risks, immune effects, or long-term adverse-event rates.
Risks of self-injection and non-prescribed peptides
Self-injection with non-prescribed peptides can add risks unrelated to the peptide itself, including contamination, dosing error, injection-site infection, and poor storage. Sterile preparation standards and clinician oversight are important safeguards for products intended for human use 8.
Does Chia offer FOXO4-DRI?
Chia does not currently offer FOXO4-DRI. It is not in our public treatment catalog, and we do not present research-use FOXO4-DRI as a prescribed longevity option.
How Chia handles treatments it does offer
For treatments Chia does offer, the process is 100% online: a short health questionnaire, then a licensed US provider review. A prescription is never guaranteed. If treatment is appropriate, medication is compounded in the US by a state-licensed 503A pharmacy and shipped to the patient’s door 3.
That model is different from buying a research chemical online. Chia’s care team can guide dosing over time for eligible prescribed treatments, and patients can message their care team through the patient portal between visits.
Related Chia longevity and metabolic-health options to discuss with a clinician
If your real goal is longevity support, energy, recovery, or metabolic health, a licensed clinician can help sort evidence from hype. Chia’s current longevity-related options include NAD+ injection or nasal spray, glutathione injection or nasal spray, sermorelin injection, nasal spray, or tablets, and GHK-Cu cream. Chia also offers the Foundation Longevity protocol, which combines sermorelin injection, NAD+ injection, and glutathione injection.
These are not the same as FOXO4-DRI, and none should be described as proven human lifespan-extension treatments. They are clinician-reviewed options for specific goals, with evidence limits and safety considerations that should be discussed before treatment.
If you want a clinician to review your goals and health history, you can start with Chia’s online eligibility quiz. The quiz is not a prescription, and treatment is prescribed only when clinically appropriate.
How does FOXO4-DRI compare with Chia’s available longevity peptides?
FOXO4-DRI is a research-stage senolytic peptide, while Chia’s listed options are clinician-reviewed treatments in our current catalog. The right comparison is not “which one is strongest,” but what evidence exists, what form is available, and what risks are known.
| Option | What it is | Chia availability | Forms listed in Chia catalog | Evidence and limits |
|---|---|---|---|---|
| FOXO4-DRI | Experimental senolytic peptide designed to disrupt FOXO4-p53 signaling | Not offered | None | Cell and mouse evidence; no established human therapy, dose, or safety profile 1, 2 |
| NAD+ | A molecule involved in cellular energy and redox biology 10 | Offered | Injection from $179/mo; nasal spray from $119/mo | Discuss with a clinician for goal fit and evidence limits; not proven to extend human lifespan |
| Glutathione | A major antioxidant system involved in redox balance 11 | Offered | Injection from $179/mo; nasal spray from $179/mo | May be discussed for oxidative-stress support goals; not a proven human lifespan-extension treatment |
| Sermorelin | A growth-hormone-releasing hormone analog used to stimulate the GH axis 12 | Offered | Injection from $179/mo; nasal spray from $179/mo; tablets | Requires clinician review because GH-axis therapies may not fit every patient |
| GHK-Cu | A copper peptide studied in skin and tissue biology 13 | Offered | Cream from $159/mo | Topical use is different from injectable research peptides; discuss skin goals and safety fit with a clinician |
Evidence limits for longevity peptides
Longevity is a high bar. A compound can affect a cell pathway, a biomarker, or an animal outcome without proving that it helps people live longer or healthier lives. That is why we describe evidence by level: cell, animal, human observational, or human randomized trial.
Even human senolytic research is still early. For example, a small first-in-human pilot study of dasatinib plus quercetin in idiopathic pulmonary fibrosis reported feasibility measures, but it was not proof that all senolytics improve aging or extend lifespan 9.
Why none should be described as proven human lifespan-extension treatments
No peptide in this article should be described as proven to extend human lifespan. For Chia-offered treatments, our role is to provide a licensed evaluation, explain realistic goals, review risks and contraindications, and prescribe only when clinically appropriate.
What should you ask a clinician before using any peptide?
Before using any peptide, ask what human evidence exists, what the regulatory status is, and what safety plan applies. For any peptide, the access path matters as much as the molecule.
- What evidence supports this use in humans: cell, animal, observational, or randomized trial data?
- Is the product FDA approved for this use, or is it a compounded medication prescribed under clinician supervision?
- What side effects, contraindications, and drug interactions are known or suspected?
- What labs, symptoms, or follow-up should be monitored?
- What pharmacy is preparing the medication, and is it a state-licensed 503A pharmacy when compounding is used?
- What is the plan if side effects occur?
- Is there a clear reason this peptide fits my goals better than lifestyle, nutrition, sleep, resistance training, or better-studied medical options?
For treatments Chia offers, you can start with the eligibility quiz and have your information reviewed by a licensed US provider. For FOXO4-DRI specifically, Chia does not offer it, and this article should not be used as a sourcing or self-experimentation guide.
FAQ
No. FOXO4-DRI is not an FDA-approved medication for human use. FDA approval applies to specific reviewed drug products, not research-use peptide vials sold online.
The evidence discussed here is mainly cell and animal research. The supplied studies do not establish completed human randomized trial evidence for FOXO4-DRI safety, dosing, or efficacy.
No. A research-use product is not the same as a medication prescribed by a licensed clinician and prepared by an appropriate pharmacy. Prescribed care includes eligibility review, safety screening, dosing guidance, and follow-up.
No. FOXO4-DRI is not in Chia’s current public treatment catalog. Chia does offer other clinician-reviewed longevity-related treatments, including NAD+, glutathione, sermorelin, and GHK-Cu, depending on eligibility.
No human evidence shows that FOXO4-DRI reverses aging or extends lifespan in people. The current evidence is preclinical, so human benefits and risks remain unknown.
Start with a licensed clinician review. Ask what human evidence exists, what the safety plan is, whether the product is prescribed and prepared through an appropriate pharmacy, and whether it fits your health history.
No. Compounded medications are not FDA-approved. At Chia, treatments require a licensed-provider evaluation and are prescribed only when clinically appropriate; a prescription is not guaranteed.
References
- 1.Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017.
- 2.FOXO4-DRI regulates endothelial cell senescence via the P53 pathway. 2025.
- 3.U.S. Food and Drug Administration. Compounded Drugs: Questions and Answers. 2024.
- 4.U.S. Food and Drug Administration. Human Drug Compounding. 2026.
- 5.U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. 2024.
- 6.Campisi J. Aging, cellular senescence, and cancer. Annual Review of Physiology. 2013.
- 7.Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017.
- 8.United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2023.
- 9.Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019.
- 10.Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021.
- 11.Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Molecular Aspects of Medicine. 2009.
- 12.DailyMed. Sermorelin acetate injection, powder, lyophilized, for solution. 2024.
- 13.Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative Medicine and Cellular Longevity. 2012.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
